101. Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy
- Author
-
Grace Liu, Liguang Chen, Bing Cui, Richard Schwab, Zhuhong Zhang, Christina C.N. Wu, Rongrong Wu, Dennis A. Carson, Emanuela M. Ghia, Thomas J. Kipps, Hsien Lai, George F. Widhopf, and Suping Zhang
- Subjects
Population ,Immunoblotting ,Transplantation, Heterologous ,Kaplan-Meier Estimate ,Mice, SCID ,Biology ,Receptor Tyrosine Kinase-like Orphan Receptors ,Small hairpin RNA ,Cancer stem cell ,Mice, Inbred NOD ,Cell Line, Tumor ,Spheroids, Cellular ,medicine ,Gene silencing ,Animals ,Humans ,Molecular Targeted Therapy ,education ,Mice, Knockout ,Ovarian Neoplasms ,education.field_of_study ,Multidisciplinary ,Microscopy, Confocal ,Oncogene ,Reverse Transcriptase Polymerase Chain Reaction ,Gene Expression Profiling ,Antibodies, Monoclonal ,Biological Sciences ,medicine.disease ,Prognosis ,Gene Expression Regulation, Neoplastic ,ROR1 ,Cancer research ,Neoplastic Stem Cells ,Female ,RNA Interference ,Stem cell ,Ovarian cancer - Abstract
Although initially responsive to chemotherapy, many patients with ovarian cancer subsequently develop relapsed and potentially fatal metastatic disease, which is thought to develop from cancer stem cells (CSCs) that are relatively resistant to conventional therapy. Here, we show that CSCs express a type I receptor tyrosine kinase-like orphan receptor (ROR1), which is expressed during embryogenesis and by many different cancers, but not normal postpartum tissues. Ovarian cancers with high levels of ROR1 had stem cell-like gene-expression signatures. Furthermore, patients with ovarian cancers with high levels of ROR1 had higher rates of relapse and a shorter median survival than patients with ovarian cancers that expressed low-to-negligible amounts of ROR1. We found that ROR1-positive (ROR1(+)) cells isolated from primary tumor-derived xenografts (PDXs) also expressed aldehyde dehydrogenase 1 (ALDH1) and had a greater capacity to form spheroids and to engraft immune-deficient mice than did ROR1-negative (ROR1(Neg)) ovarian cancer cells isolated from the same tumor population. Treatment with UC-961, an anti-ROR1 mAb, or shRNA silencing of ROR1 inhibited expression of the polycomb ring-finger oncogene, Bmi-1, and other genes associated with the epithelial-mesenchymal transition. Moreover, shRNA silencing of ROR1, depletion of ROR1(+) cells, or treatment with UC-961 impaired the capacity of ovarian cancer cells to form spheroids or tumor xenografts. More importantly, treatment with anti-ROR1 affected the capacity of the xenograft to reseed a virgin mouse, indicating that targeting ROR1 may affect CSC self-renewal. Collectively, these studies indicate that ovarian CSCs express ROR1, which contributes to their capacity to form tumors, making ROR1 a potential target for the therapy of patients with ovarian cancer.
- Published
- 2014